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ABSTRACT 
Objective: The objective of the present work was to prepare an optimized, fast dissolving tablet (FDT) of Pitavastatin to increase its dissolution by 
applying 32full factorial design. 
Methods: Nine formulations (PF1 to PF9) with all possible combinations according to 32full factorial design by selecting two factors i.e. 
concentration of super disintegrant, Indion414 (5-15%) (A) and sublimating agent, camphor (40-60%) (B) as independent variables at three levels 
of-1, 0 and 1. The effect of these two variables on three dependent parameters, water absorption ratio (Y1), disintegration time (Y2) and in vitro 
drug release (Y3) was studied. All the powder blends were evaluated for precompression parameters, and the tablets were prepared by direct 
compression method which were further evaluated for post-compression parameters. The effect of change in concentration of two selected factors 
on dependent parameters was studied through 3D surface response plots and polynomial equations using Design expert software version11. 
Optimized formula was obtained by desirability and overlay plots for which compatibility stability was assessed.  
Results: Precompression and post-compression parameters were satisfactorily within acceptable limits. Optimized formulation was prepared to 
prove the validity of the evolved mathematical model, which contained 6.75 mg of indion414(0.9) and 54 mg of camphor(0.9) with a disintegration 
time of 21 sec., water absorption ratio of 113 and 93% of drug release within 12 min. The compatibility between drugs and excipients was proved. 
The dissolution profiles of optimized formulation and commercially available conventional film-coated tablets of Pitavastatin were compared.  
Conclusion: The optimized formulation showed significantly (P>0.05) increased drug release compared to commercially available film-coated 
tablets. No changes in disintegration time, drug content and in in vitro drug release from optimized formulation on storage for 3months at 40 °C±2 
°C/75% RH±5% RH were observed during stability studies which confirmed the stability of the optimized formulation. 
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INTRODUCTION 
Nutritional and lifestyle changes in recent decades lead to many 
chronic diseases such as dyslipidemia. Dyslipidemia creates a serious 
problem all over the world as it was found as the primary factor for 
many heart illnesses resulting in mortality and expensive treatment. 
Dyslipidemia triggers various heart diseases such as atherosclerosis, 
cardiac infarction and ischemic heart diseases. Statins are one of the 
extensively prescribed medications to minimize the deaths due to 
Angina pectoris in hyperlipidemic patients [1]. All statins are available 
in conventional tablet formulations with very limited bioavailability. 
Pitavastatin comparatively novel derivative of statin family, it has 
unique pharmacological benefits in the reduction of low-density 
lipoprotein–cholesterol (LDL-C) and improvement of high-density 
lipoprotein-cholesterol (HDL-C) which is used in the treatment of 
many cardiovascular diseases [2]. Pitavastatin offered in film-coated 
tablets that cannot be crushed or chewed or swallowed easily by 
patients and is not available as liquid dosage forms. Pitavastatin is not 
useful in emergency clinical conditions of cardiovascular disease 
because of low solubility and slow onset of action. As there is an 
increased use of statins for the pediatric and geriatric population, 
there is a need to develop fast dissolving tablets of Pitavastatin for 
easy swallowing and fast onset of action. 
The fast-dissolving tablets (FDTs) disintegrate and dissolve within 
seconds and are meant for administration to the patients who 
cannot swallow, such as elderly patients, stroke victims, bedridden 
patients, patients affected by renal failure, and patients who refuse 
to swallow, such as pediatric, geriatric, and psychiatric patients [3]. 
Hence, the present study was aimed at preparation of fast dissolving 
tablets of Pitavastatin using super disintegrant (Indion414) [4] and 
sublimating agent (camphor) [5] by direct compression method 
following 32 factorial design for the best-optimized formulation to 
increase dissolution of the drug, further to enhance absorption and 
bioavailability of drug for treating emergency clinical conditions of 
cardiovascular diseases.  
MATERIALS AND METHODS 
Materials 
Pitavastatin was obtained as a gift sample from Aizant pharm labs 
(Hyderabad, India) Indion414 was purchased from Balaji drugs 
(Gujarat, India), microcrystalline cellulose, mannitol, magnesium 
stearate and aerosil were obtained from SD fine chemicals. 
Methods 
Factorial experimental design 
Formulation of fast dissolving tablets (FDT) of Pitavastatin was 
designed according to 32 full factorial design using two independent 
variables, [6, 7] A (concentration of indion414, a super disintegrant) and 
B (concentration of camphor, a sublimating agent) at three (low, medium 
and high) levels of each variable (-1, 0 and 1) as given in table 1. The 
dependent parameters selected were water absorption ratio (Y1), 
disintegration time (Y2) and in vitro drug release (Y3). The software, 
design expert from Stat-Ease 11 version [8] was used for generating the 
experimental design from which the polynomial equations, surface 
response plots were obtained to find the impact of change in selected 
variables in three levels on Y1, Y2 and Y3. The desirability and overlay 
plots were generated to collect the composition of the best-optimized 
formulation along with the predicted values for Y1, Y2 and Y3 and 
calculated the validity of the design. 
Formulation of FDT 
Thus, a total of nine formulations of FDT of Pitavastatin was 
prepared by the direct compression method as per the composition 
shown in table 2. Pitavastatin, indion414, camphor, microcrystalline 
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cellulose and mannitol were accurately weighed and passed through 
sieve no 40 and were mixed well for 30 min to assure uniform 
distribution of the drug. Then, magnesium stearate and aerosil were 
added and mixed well [9, 10]. All materials were directly 
compressible, so the uniformly mixed blend was compressed into 
tablets using 7 mm punches on a twelve station tablet punching 
machine (Remek Minipress) [11]. All formulations were evaluated 
for different pre-compression and post-compression parameters. 
 
Table 1: Coded and actual values of independent variables as per 32factorial design 
Formulation code Superdisintegrant (A) values Sublimating agent (B) values 
Coded Actual (mg.) Coded Actual (mg.) 
PF1 -1 2.5 -1 40 
PF2 -1 2.5 0 50 
PF3 -1 2.5 1 60 
PF4 0 5 -1 40 
PF5 0 5 0 50 
PF6 0 5 1 60 
PF7 1 7.5 -1 40 
PF8 1 7.5 0 50 
PF9 1 7.5 1 60 
Optimized formula 0.9 6.75 0.9 54 
 
Table 2: Composition of different pitavastatin fast dissolving tablets 
Ingredients (mg) PF1 PF2 PF3 PF 4 PF5 PF 6 PF7 PF8 PF 9 Optimized formula 
Pitavastatin 4 4 4 4 4 4 4 4 4 4 
Indion414 2.5 2.5 2.5 5 5 5 7.5 7.5 7.5 6.75 
Camphor 40 50 60 40 50 60 40 50 60 54 
Microcrystalline cellulose 49.5 39.5 29.5 47 37 27 44.5 34.5 24.5 31.25 
Mannitol 50 50 50 50 50 50 50 50 50 50 
Aerosil 2 2 2 2 2 2 2 2 2 2 
Magnesium Stearate 2 2 2 2 2 2 2 2 2 2 




The powder blend was subjected to test the parameters before 
compression to tablets such as the angle of repose, bulk density, tapped 
density, Carr’s index and Hausner’s ratio using standard procedures [12]. 
Post compression parameters 
Thickness, hardness and weight variation test 
Thickness was determined for 20 pre-weighed tablets of each batch 
using a vernier calipers scale. Average of three readings were taken 
for each tablet and the results were tabulated. The hardness of five 
tablets was determined by Monsanto hardness tester then, the 
average hardness value was calculated and expressed in kg/cm2. 
Randomly selected 20tablets of each batch were individually 
weighed using electronic balance, then, the average weight was 
calculated. The percentage deviation of each tablet weight from the 
average weight was tabulated. 
Friability test 
The friability of tablets was estimated using Roche friabilator. It was 
expressed in percentage (%) loss on friability. 10 tablets were pre-
weighed and the weight was noted as initial weight and conveyed 
into friabilator, which was run at 25 rpm for 4 min. Then, the tablets 
were de-dusted, weighed again and the weight was noted as final 
weight. The percentage loss on friability was calculated with the 
difference in these weights which should be less than 4% for oral 
disintegrating and chewable tablets. 
Wetting time and Water absorption ratio(R) (Y1)  
Five circular tissue papers of 10 cm diameter were placed in a petri 
dish. 10 ml of water was added to petri dish, a tablet was carefully 
placed on the surface of each tissue paper. The time taken for water 
to reach the upper surface of the tablet was noted as wetting time. 
The weight of the tablet before keeping in the petri dish was noted 
(Wb). Then the completely wetted tablet from petri dish was taken 
and reweighed (Wa). The water absorption ratio (R), was calculated 
by an equation: R=100(Wa-Wb)/Wb [13]. 
Drug content 
Ten tablets were selected randomly and crushed in a mortar and an 
accurately weighed amount of an average tablet was taken from the 
crushed blend. Then, the sample was transferred to the 100 ml 
volumetric flask and diluted up to the mark with pH6.8 phosphate buffer. 
It was shaken and kept for 24 h for dissolving drugs completely. The 
drug content was estimated at λ max of 245 nm against pH 6.8 phosphate 
buffer as a blank using a UV-Visible spectrophotometer after filtration 
and dilution. Then the average of triplicate measurements was taken and 
%drug content was recorded for all batches. 
Disintegration time (Y2) 
The disintegration test was carried out in a tablet disintegration test 
apparatus containing a basket rack assembly with six glass tubes 
and a 10 mesh sieve at the bottom. The basket was raised and 
lowered 28-32 times per minute in the medium of 900 ml of pH 6.8 
phosphate buffer was maintained at 37±2 °C. Six tablets were placed 
in each of the tubes and the time required for complete passage of 
tablet fragments through the sieve (# 10) was considered as the 
disintegration time of the tablet and the average disintegration time 
of FDTs was tabulated. 
In vitro dissolution studies (Y3) 
In vitro drug release studies were carried out for all (PF1-PF9) 
formulations and commercial film-coated tablets of Pitavastatin 
using USP dissolution test apparatus II (paddle type) at 50 rpm. in 
900 ml of pH6.8 phosphate buffer maintained at 37±0.5 °C. A sample 
of 5 ml was withdrawn at specific time intervals (5, 10,15,20,25 and 
30 min), filtered and the amount of drug released was estimated by 
UV-Visible spectrophotometer (Lab India, Mumbai) at 245 nm. 5 ml 
of fresh pH6.8 phosphate buffer was replaced as soon as the drug 
samples were withdrawn. Percentage of drug dissolved and 
dissolution rate was determined in triplicate. 
Optimized formulation 
The optimized formula (table 2) was collected from the overlay plot 
and desirability plot obtained using the results of Y1, Y2 and Y3 of all 
formulations (PF1-PF9) by design expert software and the optimized 
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FDT (OFDT) formulation were prepared using the formula and 
evaluated by the same procedures. The design predicted and observed 
values of dependent variables (Y1, Y2 and Y3) of OFDT were compared 
and %error was determined. Dissolution profiles of prepared OFDT 
and conventional film-coated tablets of Pitavastatin were compared. 
OFDT was further evaluated for compatibility and stability [14, 15]. 
Drug and excipient compatibility studies 
The compatibility between drug and excipients was estimated by 
recording Fourier Transform Infra-Red (FTIR) spectra on a FTIR 
spectroscopy (Bruker Germany,) with KBr disc technique in the scanning 
range of 4,000–400 cm−1and by Differential Scanning Calorimetric 
(DSC) thermograms for both pure drug and optimized formulation. 
Stability studies 
Stability studies were conducted for the optimized formulation as 
per International Council for Harmonisation (ICH) guidelines by 
placing in a glass container which was sealed in aluminum packaging 
and kept in stability chamber maintained at 40 °C±2 °C/75% RH±5% 
RH for 3 mo [16]. 
RESULTS AND DISCUSSION 
32full factorial design was used in present research, in which the 
influence of two variables, percentage of super disintegrant, 
indion414 (A) and sublimating agent, camphor (B) each at three 
levels on water absorption ratio (Y1), disintegration time (Y2), and 
in vitro drug release (Y3) was evaluated by preparing FDT 
formulations at all nine possible combinations (PF1-PF9). 
From the results of pre-compression parameters of powder blend 
(table 3), it was observed that all parameters were within the range 
of good flow properties and concluded that the powder blends 
possessed good flow properties and acceptable compressibility 
index; hence all were suitable for formulation development similar 
to the reports of Patel DM et al. [17]. 
 
Table 3: Results of pre-compression parameters of pitavastatin fast dissolving tablet (PF1-PF9) formulation blends 




Carr’s index Hausner’s ratio 
PF1 29.5±0.8 0.64±0.4 0.78±0.5 17.9±0.9 1.21±0.7 
PF2 29.1±1.2 0.68±0.3 0.76±0.5 10.5±1.0 1.11±1.1 
PF3 27.2±0.1 0.61±1.0 0.73±0.9 16.4±0.9 1.19±0.8 
PF4 32.5±0.7 0.58±0.7 0.70±0.5 17.1±1.1 1.21±0.9 
PF5 28.7±1.0 0.66±0.3 0.76±0.4 13.1±0.6 1.15±0.8 
PF6 23.8±0.2 0.65±0.2 0.74±0.3 12±0.3 1.13±0.5 
PF7 30.2±0.6 0.70±0.8 0.78±0.8 10.2±0.8 1.11±1.0 
PF8 26.5±0.3 0.69±0.9 0.78±0.8 11.5±0.9 1.13±1.1 
PF9 27.7±0.2 0.73±1.0 0.81±1.1 9.8±0.7 1.10±0.9 
n=3, all values represent mean±SD 
 



















PF1 3.4±0.2 2.6±0.1 0.133±0.5 0.74±1.1 35±1.0 45±0.5 80±0.3 98.5±0.5 
PF2 3.3±0.1 2.4±0.2 0.066±0.006 0.94±0.6 31±1.0 65±1.0 53±0.5 99.3±0.3 
PF3 3.6±0.2 2.5±0.1 0.266±0.01 0.84±0.8 28±1.0 63±0.6 68±0.6 99.7±0.1 
PF4 3.5±0.1 2.7±0.3 0.266±0.01 0.75±1.2 39±1.0 72±0.8 58±1.2 98.7±0.2 
PF5 3.2±0.4 2.8±0.5 0.123±0.02 0.99±1.0 29±1.0 76±1.2 45±0.8 98.6±0.5 
PF6 3.3±0.1 2.8±0.2 0.136±0.05 0.11±1.1 22±1.0 93±0.8 38±0.7 99.5±0.6 
PF7 3.5±0.1 2.5±0.3 0.210±0.08 0.83±0.6 26±1.0 80±1.2 76±0.4 98.5±0.3 
PF8 3.2±0.3 2.1±0.2 0.064±0.001 0.66±0.9 23±1.0 88±0.6 28±0.5 98.8±0.5 
PF9 3.3±0.1 2.6±0.2 0.124±0.01 0.84±1.0 21±1.0 135±0.8 20±1.2 99.4±0.4 
an=3, bn=5,cn=20,dn=10,en=6, all values represent mean±SD 
 
 
Fig. 1: In vitro drug release profiles of pitavastatin fast dissolving tablets, n=3 
 
The results of post-compression parameters (table 4) indicated 
that the hardness, weight variation, friability of all the 
formulations were within the range of IP limits. Wetting time of 
all the formulations was found to be in the range of 21 to 39 
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seconds, less wetting time of formulation is an indication of fast 
disintegration, water absorption ratio was in the range of 45 
to135 and disintegration time was 20 to 80 seconds. The PF9 
formulation consisted of high levels of super disintegrant and 
sublimating agent has shown the least disintegration time and 
the highest water absorption ratio might be due to remarkable 
moisture absorbing and swelling properties of indion 414 and 
volatilization of camphor caused creation of pores and 
absorption of more water through pores which were supported 
by the results of Salch AER [18]. The drug content of all 
formulation was within 98.5 to 99.7%. 
The in vitro drug release studies of all formulation batches (PF1-PF9) 
(fig. 1) shown significantly enhanced drug release (PF7-PF9 as compared 
to PF1-PF3) with the increased concentrations of super disintegrant 
(indion414) and camphor (sublimating agent). Among all the 
formulations, PF9 has shown the highest percentage drug release (95%) 
within 12 min. 
Factorial design–data analysis 
The polynomial equations (linear equations) were generated by 
design (table 5) and 3D response surface plots resulting from 
equations were obtained by design expert software (fig. 2). 
  
  
(a) Water absorption ratio (b) In vitro disintegration time 
 
(c) In vitro drug release studies 
Fig. 2: 3D surface response plots for a) Water absorption ratio (Y1) b) Disintegration time (Y2) c) In vitro drug release (Y3) of pitavastatin 
fast dissolving tablets 
 
Table 5: Polynomial equations for selected responses generated by design 
Eq. No. Name of response Polynomial Equation 
1 Water absorption ratio (Y1) Y1=+79.67+21.67A+15.67B 
2 Disintegration time (Y2) Y2=37.22-12.83A-14.67B 
3 In vitro Drug release (Y3) Y3=71.78+11.67A+12.50B 
 
The formulations were analysed for three selected critical 
parameters for which three polynomial equations were generated 
according to the results of parameters from software (table.5). The 
magnitude and sign of coefficients of two variables in three 
equations indicated the extent and trend of influence of two 
variables (A and B) on three responses (Y1, Y2 and Y3). A positive 
sign implicated a synergistic effect and negative sign indicated an 
antagonistic effect of the variable on responses.  
The overall conclusion of influence of A and B variables 
(Concentration of Indion414 and camphor)was positive on Y1 
(water absorption ratio) and Y3(in vitro drug release) indicated that 
increased concentrations of two variables enhanced the water 
absorption and drug release due to its high moisture absorption and 
fast disintegration capacity of tablets. The effect of two variables was 
negative on Y2 (disintegration time) indicated that disintegration 
time was decreased with an increase in concentrations of A and B 
due to same reason. Among two variables, the magnitude of A in 
equation 1was highest implied the more influence of concentration 
of Indion (A) on water absorption ratio than on all other responses. 
Further numerical and graphical optimization of variables were 
obtained by desirability and overlay plots (fig. 3) 
As per numerical optimization, the overall desirability of optimized 
formulation was found to be near to one (0.99) in the desirability 
plot (fig. 3a.). Then the optimized tablets were prepared according to 
composition obtained in overlay plot (fig. 3b) as per the design and 
evaluated for three dependent parameters, water absorption ratio, 
disintegration time and in vitro drug release in 12 min. and the 
results were 113, 21 sec. and 93% respectively which were 
compared with the model predicted values. The high water 
absorption ratio of OFDT is contributed for its least disintegration 
time and more drug release. The % prediction error was less than 
5% (table 6), hence the validity of the design and optimized 
formulation was confirmed. 
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a)       (b) 
Fig. 3: a) Desirability plot b) Overlay plot of pitavastatin fast dissolving tablets by 32full factorial design 
 
Table 6: The model suggested an optimum formula with predicted and observed values of responses 
Independent 
variables 




% of prediction error 
Coded Actual (mg.) 
A 0.9 6.75 Y1 113.26 a125.5±0.5 -10.4 
B 0.9 54 Y2(sec.) 21.24 b18.21±1.0 -14.2 




Fig. 4: Comparative in vitro dissolution profiles of marketed and optimized pitavastatin fast dissolving tablets, n=3 
 
Drug release profiles of optimized formulation and commercially 
available film-coated tablets of Pitavastatin, (fig. 4) were compared. 
Drug release from optimized formulation was significantly enhanced 
(p≥0.05) compared to the commercial formulation. 
 
 
Fig. 5a: FT-IR spectrum of a pure drug (pitavastatin) 
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Fig. 5b: FT-IR Spectrum of pitavastatin formulation 
 
FTIR spectrum of Pitavastatin (fig. 5a) shown characteristic peaks at 
1433.7 cm-1 due to C=C bending, peak at 1658.70 cm-1 indicated C=O 
stretching, peak at 2948.82 cm-1 indicated the presence of C-H 
stretching, peak at 3396.79 cm-1 indicated O-H stretching and peak 
at 3858.3 cm-1 represented N-H stretching. Based on fig. 5b, no 
changes were found in the main bands of a drug due to the presence 
of excipients in optimized formulation; hence it revealed the 
physical and chemical compatibility between drug and excipients. 
 
 
Fig. 6: DSC thermograms of pitavastatin pure and its optimized formulation 
 
Table 7: Results of all parameters on stability studies of optimized formulation 
S. No Test parameter 0 d 30 d 90 d 
1 aThickness (mm) 3.5±0.1 3.50.1 3.50.1 
2 aHardness(kg/cm²) 2.2±0.3 2.2±0.3 2.2±0.2 
3 aWeight (mg) 149.5±0.5 149.5±0.6 149.3±0.5 
4 b% loss in friability 0.65±0.3 0.65±0.5 0.64±0.6 
5 aWetting time(sec) 15±1.0 16±0.5 16±1.0 
6 aWater absorption ratio 125±0.3 128±0.5 123±0.3 
7 aDrug content (%) 101.5±0.3 101.1±0.2 101±0.6 
8 cDisintegration time(sec) 18±1.0 20±1.2 21±1.0 
9 aIn vitro drug release (%) 96.6±0.2 92±0.6 93±0.5 
 an=3,bn=10,cn=6, All values represent mean±SD 
Dasari et al. 
Int J App Pharm, Vol 12, Issue 1, 2020, 108-114 
114 
DSC thermograms of pure Pitavastatin and optimized formulation 
are shown in fig 6. A sharp endothermic peak was observed at 139 
°C in the case of pure pitavastatin reflecting the purity in crystalline 
form. The intensity of peak was less sharp and suppressed in case of 
optimized formulation might be due to decreased crystallinity of 
drugs upon compression into a tablet using a sublimating agent. 
The results of short term stability studies indicated that the post-
compression parameters were satisfactory within the limits after 
storage for 90 d. In vitro drug release profile also not changed on 
storage. Hence, stability studies confirmed the stability of prepared 
optimized formulation (table 7). 
CONCLUSION 
Fast dissolving tablets of Pitavastatin were prepared and optimized 
using 32 full factorial design. The concentration of indion414 and 
camphor were selected as two independent variables which 
significantly (p<0.05) affected the dependent parameters, water 
absorption ratio, disintegration time and drug release. Design expert 
trial version11 was used to optimize and to draw respective 
polynomial equations, response surface plots. A stable optimized 
formulation was prepared as per composition generated by numerical 
and graphical optimization in the form of desirability and overlay 
plots. The optimized formulation exhibited a water absorption ratio of 
113, disintegration time of 21 sec. and drug release of 93% within 12 
min which were closed to predicted values confirmed the validity of 
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